Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: Results of a randomized, controlled trial

Highlights ► An evaluation of Canadian-made AS03-adjuvanted H1N1pdm09 vaccine in adults. ► Evaluation included compatibility with trivalent inactivated influenza (TIV) vaccine. ► One dose of H1N1pdm09 vaccine (3.75 μg) was sufficiently immunogenic. ► Concurrent dosing did not adversely affect immune...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-07, Vol.30 (32), p.4728-4732
Main Authors: Scheifele, David W, Ward, Brian J, Dionne, Marc, Vanderkooi, Otto G, Loeb, Mark, Coleman, Brenda L, Li, Yan
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Adult
adults
adverse effects
Age
Allergy and Immunology
Antibodies, Viral - blood
blood
Female
hemagglutination
Hemagglutination Inhibition Tests
Humans
influenza
Influenza A Virus, H1N1 Subtype - immunology
Influenza vaccine, A/H1N1pdm09 pandemic
Influenza vaccine, seasonal
Influenza Vaccines - administration & dosage
Influenza Vaccines - adverse effects
Influenza Vaccines - immunology
Influenza, Human - immunology
Influenza, Human - prevention & control
interviews
Male
Medical research
Middle Aged
pandemic
Public health
seroprevalence
Studies
vaccination
Vaccination - methods
Vaccine adjuvants
Vaccines
Vaccines, Inactivated - administration & dosage
Vaccines, Inactivated - adverse effects
Vaccines, Inactivated - immunology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► An evaluation of Canadian-made AS03-adjuvanted H1N1pdm09 vaccine in adults. ► Evaluation included compatibility with trivalent inactivated influenza (TIV) vaccine. ► One dose of H1N1pdm09 vaccine (3.75 μg) was sufficiently immunogenic. ► Concurrent dosing did not adversely affect immune responses to either vaccine. ► Concurrent vaccinations did not increase rates of systemic symptoms.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.05.029